Zacks Research Forecasts Lower Earnings for Gilead Sciences

Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) – Equities research analysts at Zacks Research lowered their FY2026 EPS estimates for shares of Gilead Sciences in a report released on Thursday, November 12th. Zacks Research analyst Team now expects that the biopharmaceutical company will post earnings per share of ($0.86) for the year, down from their prior forecast of ($0.65). Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Gilead Sciences’ current full-year earnings is ($0.97) per share. Zacks Research also issued estimates for Gilead Sciences’ Q4 2026 earnings at $1.31 EPS, Q4 2027 earnings at $2.58 EPS and Q1 2028 earnings at $2.16 EPS.

A number of other equities analysts have also recently weighed in on the stock. Sanford C. Bernstein reissued an “outperform” rating and set a $175.00 price target on shares of Gilead Sciences in a research report on Monday, November 2nd. JPMorgan Chase & Co. upped their price objective on shares of Gilead Sciences from $170.00 to $190.00 and gave the company an “overweight” rating in a research report on Friday, October 30th. Argus set a $190.00 price objective on shares of Gilead Sciences in a research report on Thursday. UBS Group raised their price objective on Gilead Sciences from $175.00 to $195.00 and gave the stock a “buy” rating in a research note on Friday, October 30th. Finally, Jefferies Financial Group set a $196.00 target price on Gilead Sciences in a report on Wednesday, November 4th. Twenty-three research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus price target of $171.07.

Read Our Latest Stock Analysis on Gilead Sciences

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $168.08 on Monday. The company has a 50 day moving average price of $155.10 and a two-hundred day moving average price of $141.80. The company has a debt-to-equity ratio of 1.84, a quick ratio of 1.22 and a current ratio of 1.38. The company has a market capitalization of $208.48 billion, a PE ratio of -53.19 and a beta of 0.35. Gilead Sciences has a 52 week low of $116.88 and a 52 week high of $176.58.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last issued its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.19 by $0.36. The firm had revenue of $8.30 billion during the quarter, compared to analysts’ expectations of $7.81 billion. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The business’s revenue for the quarter was up 6.8% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.47 earnings per share.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 30th. Shareholders of record on Tuesday, December 15th will be paid a $0.82 dividend. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.0%. Gilead Sciences’s payout ratio is presently -103.80%.

Insider Transactions at Gilead Sciences

In other news, Director Anthony Welters sold 18,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $148.62, for a total value of $2,675,160.00. Following the completion of the transaction, the director owned 12,894 shares in the company, valued at $1,916,306.28. This represents a 58.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel O’Day sold 102,619 shares of the stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $175.16, for a total transaction of $17,974,744.04. Following the sale, the chief executive officer directly owned 551,683 shares of the company’s stock, valued at $96,632,794.28. This represents a 15.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 211,709 shares of company stock valued at $35,234,427. 0.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Gilead Sciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GILD. Bank of Nova Scotia acquired a new position in shares of Gilead Sciences during the 2nd quarter worth approximately $100,056,000. OMERS ADMINISTRATION Corp bought a new stake in shares of Gilead Sciences during the 2nd quarter worth approximately $55,754,000. Groupe la Francaise boosted its holdings in shares of Gilead Sciences by 30.9% in the 2nd quarter. Groupe la Francaise now owns 49,627 shares of the biopharmaceutical company’s stock valued at $6,270,000 after buying an additional 11,712 shares during the last quarter. Baird Financial Group Inc. boosted its holdings in shares of Gilead Sciences by 3.6% in the 2nd quarter. Baird Financial Group Inc. now owns 292,295 shares of the biopharmaceutical company’s stock valued at $36,929,000 after buying an additional 10,206 shares during the last quarter. Finally, Headlands Technologies LLC acquired a new stake in shares of Gilead Sciences in the 2nd quarter valued at approximately $6,251,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Gilead Sciences

These are some of the GILD headlines that stood out recently:

  • Positive Sentiment: Zacks Research raised several forecasts, including FY2027 EPS to $9.42 from $9.36 and FY2028 EPS to $9.69 from $9.66. It also made small upward adjustments to quarterly estimates. The revisions suggest slightly improved expectations, though the analyst’s Hold rating tempers the signal.
  • Neutral Sentiment: Gilead announced a partnership with TelevisaUnivision to promote HIV-prevention awareness at the Latin GRAMMY Awards. It may build awareness, but the announcement does not specify a direct near-term financial impact. Read More..
  • Neutral Sentiment: A broader pharmaceutical-stock article highlighted Gilead’s dividend and pipeline as defensive attributes, but offered no company-specific new financial or operating catalyst. Read More..

About Gilead Sciences

(Get Free Report)

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.

Further Reading

Earnings History and Estimates for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.